ANALYST-UPGRADE filed Jul 6, 2026 at 05:50 ET
HSBC double-upgraded Gilead Sciences from Hold to Buy on July 6, 2026, raising its price target to $155 from $133, implying 18% upside from the current $131.27. The call is consensus-aligned: 82% of analysts rate GILD a Buy (32 of 39), with a mean target of $157.67 and a high of $180. HSBC's track record is below average at 55% accuracy on 263 calls, but the double-upgrade signals conviction. Momentum is positive with 1 upgrade and 0 downgrades in the past 30 days, and EPS revisions for the current year are trending up (3 up, 0 down in 30 days). However, insider selling by CEO O'Day ($1.9M on July 1) and a high short-interest ratio of 56.8% create a divergence with the bullish analyst signal. Earnings are due August 5, 2026, adding a near-term catalyst. The bottom line: the upgrade reinforces the bullish consensus, but traders should weigh insider sales and elevated short interest against the positive analyst momentum.